12:00 AM
Apr 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IPX066: Completed Phase III enrollment

Impax completed enrollment of 350 patients in the double-blind, placebo-controlled, North American and European Phase III APEX-PD trial evaluating 3 dose levels of oral IPX066....

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >